Australia's federal Health Minister, Kay Patterson, has said thatPfizer's erectile dysfunction drug Viagra (sildenafil) will not be subsidized under the Pharmaceutical Benefits Scheme.
Last month, the Pharmaceutical Benefits Advisory Committee had recommended that Viagra be listed (Marketletter January 28), even though the panel had reportedly put the cost to the taxpayer at over three-and-a-half times the amount estimated by Pfizer in its submission.
The Minister said she was not dismissive of the problems faced by men suffering erectile dysfunction, but the cost of listing Viagra would be over A$100 million ($51.2 million) a year. Faced with difficult choices, the government had to ensure the sustainability of the PBS, she said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze